A Forex-Nachrichten
Agilent Inks Deal With Quest Diagnostics To Offer CtDx FIRST Liquid Biopsy Test Across US
Agilent Technologies, Inc. (A) announced Monday an agreement with Quest Diagnostics (DGX), a diagnostic information services company, to enable providers and patients throughout the U.S. to access the Agilent Resolution ctDx FIRST liquid biopsy next-generation sequencing (NGS) test.
RTTNews
|
vor 646 Tagen
